Table 1.
The demographic and baseline characteristics
| Characteristics | Ceftriaxone-sulbactam | Cefoperazone-sulbactam | P |
|---|---|---|---|
| Male, n(%) |
64(44.44%) |
63(44.68%) |
0.9680 |
| Female, n(%) |
80(55.56%) |
78(55.32%) |
|
| Mean age, years(SD) |
46.00±15.86 |
46.47±14.49 |
0.9370 |
| Mean weight, kg(SD) |
59.36±11.08 |
59.61±11.29 |
0.9742 |
| Treatment duration |
8.45±3.03 |
8.10±3.00 |
0.3251 |
| Condition |
|
|
|
| Intermediate |
113 |
116 |
0.7901 |
| Severe |
31 |
25 |
0.5085 |
| Temperature(°C) |
37.19±0.79 |
37.04±0.77 |
0.0840 |
| With underlying diseases |
34 |
29 |
0.6209 |
| Type of infection, n(%) |
|
|
|
| Respiratory tract infection |
|
|
0.2348 |
| Pneumonia |
33(45.83%) |
32(44.44%) |
|
| Exacerbation of chronic bronchitis |
21(29.17%) |
15(20.83%) |
|
| Bronchiectasis |
12(16.67%) |
11(15.28%) |
|
| Others |
6(8.33%) |
14(19.44%) |
|
| Urinary tract infection |
|
|
0.8021 |
| Acute pyelonephritis |
24(33.33%) |
19(27.54%) |
|
| Exacerbation of chronic pyelonephritis |
9(12.50%) |
7(10.14%) |
|
| Acute cystitis |
33(45.83%) |
37(53.62%) |
|
| Others | 6(8.33%) | 6(8.70%) |
SD: Standard deviation.